Manipulation of the bluetongue virus tubules for immunogen delivery

Future Microbiology

Volumn 3, Issue 3, 2008, Pages 351-359

  Murphy, Aileen ^a   Roy, Polly ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bluetongue virus; Immune response; Nonreplicating; Tubules; Vaccine

Indexed keywords

DNA VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NONSTRUCTURAL PROTEIN 1; PROTEIN VP1; VIRUS VACCINE; VIRUS VECTOR; NANOPARTICLE; NS1 PROTEIN, BLUETONGUE VIRUS; RECOMBINANT VACCINE; VIRUS PROTEIN;

BLUETONGUE ORBIVIRUS; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; VIREMIA; VIRUS LIKE AGENT; GENETICS; HUMAN; IMMUNOLOGY;

BLUETONGUE VIRUS;

BLUETONGUE VIRUS; HUMANS; NANOPARTICLES; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 46049116321     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.3.351     Document Type: Review

References (46)

1. Almond JW, Westrop GD, Evans DM et al.: Studies on the attenuation of the Sabin type 3 oral polio vaccine. J. Virol. Methods 17, 183-189 (1987).
2. Stephenson I, Nicholson KG: Influenza: vaccination and treatment. Eur. Respir. J. 17, 1282-1293 (2001).
3. Boyer JD, Robinson TM, Kutzier MA et al.: Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl Acad. Sci. USA 104, 18648-18653 (2007).
4. Fouts ET, Yu X, Egelman EH, Botchan MR: Biochemical and electron microscopic image analysis of the hexameric E1 helicase. J. Biol. Chem. 274, 4447-4458 (1999).
5. Pearson LD, Roy P: Genetically engineered multi-component virus-like particles as veterinary vaccines. Immunol. Cell Biol. 71, 381-389 (1993).
6. O'Neal C, Crawford SE, Estes MK, Conner ME: Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71, 8707-8717 (1997).
7. Galarza JM, Latham T, Cupo A: Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18, 244-251 (2005).
8. Lopez de Turiso JA, Cortes E, Martinez C et al.: Recombinant vaccine for canine parvovirus in dogs. J. Virol. 66, 2748-2753 (1992).
9. Evans TG, Bonnez W, Rose RC et al.: A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493 (2001).
10. Brown CS, Welling-Wester S, Feijibrief M, Van Lent JW, Spaan WJ: Chimeric parvovirus B19 capsids for the presentation of foreign epitopes. Virology 198, 477-488 (1994).
11. Amexis G, Young NS: Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. J. Infect. Dis. 194, 790-794 (2006).
12. Zhou X, Berglund P, Zhao H, Liljestrom P, Jondal M: Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl Acad. Sci. USA 92, 3009-3013 (1995).
13. Tatsis N, Ertl HC: Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629 (2004).
14. Wyatt LS, Shors ST, Murphy BR, Moss B: Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451-1458 (1996).
15. Weir RE, Brennan PJ, Butlin CR, Dockrell HM: Use of a whole blood assay to evaluate in vitro T cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects. Clin. Exp. Immunol. 116, 263-269 (1999).
16. Koo M, Bendahmane M, Lettieri GA et al.: Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc. Natl Acad. 5d. USA 96, 7774-7779 (1999).
17. Le Blois H, Roy P: A single point mutation in the VP7 major core protein of bluetongue virus prevents the formation of core-like particles. J. Virol. 67, 353-359 (1993).
18. Belyaev AS, Roy P: Presentation of hepatitis B virus preS2 epitope on bluetongue virus core-like particles. Virology 190, 840-844 (1992).
19. Adler S, Reay P, Roy P, Klenk HD: Induction of T cell response by bluetongue virus core-like particles expressing a T cell epitope of the M1 protein of influenza A virus. Med. Microbiol. Immunol. 187, 91-96 (1998).
20. Sugiyama K, Bishop DH, Roy P: Analyses of the genomes of bluetongue viruses recovered in the United States. I. Oligonucleotide fingerprint studies that indicate the existence of naturally occurring reassortant BTV isolates. Virology 114, 210-217 (1981).
21. Huismans H: Protein synthesis in bluetongue virus-infected cells. Virology 92, 385-396 (1979).
22. Van Dijk AA, Huismans H: In vitro transcription and translation of bluetongue virus mRNA. J. Gen. Virol. 69, 573-581 (1988).
23. Huismans H, Els FIJ: Characterization of the tubules associated with the replication of three different orbiviruses. Virology 92, 397-406 (1979).
24. Urakawa T, Roy P: Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10. J. Virol. 62, 3919-3927 (1988).
25. Hewat EA, Booth TF, Wade RH, Roy P: 3-D reconstruction of bluetongue virus tubules using cryoelectron microscopy. J. Struct Biol. 108, 35-48 (1992).
26. Marshall JJ, Fayard B, Roy P: Biophysical studies on the morphology of baculovirus-expressed bluetongue virus tubules. J. Gen. Virol. 71, 1839-1844 (1990).
27. Monastyrskaya K, Booth T, Nel L, Roy P: Mutation of either of two cysteine residues or deletion of the amino or carboxy terminus of nonstructural protein NS1 of bluetongue virus abrogates virus-specified tubule formation in insect cells. J. Virol. 68, 2169-2178 (1994).
28. Owens RJ, Limn C, Roy P: Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release. J. Virol. 78, 6649-6656 (2004).
29. Gould AR, Martyn JC, Stevenson L: Expression of the non-structural protein NS1 of bluetongue virus in bacteria and yeast: identification of two antigenic sites at the amino terminus. Virus Res. 31, 291-303 (1994).
30. Monastyrskaya K, Gould EA, Roy P: Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein. J. Virol. 69, 2831-2841 (1995).
31. Mikhailov M, Monastyrskaya K, Bakker T, Roy P: A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules. Virology 217, 323-331 (1996).
32. Ghosh MK, Deriaud E, Saron MF et al.: Induction of protective antiviral cytotoxic T-cells by a tubular structure capable of carrying large foreign sequences. Vaccine 20, 1369-1377 (2002).
33. + Th cell and protective humoral responses. Virology 302, 383-392 (2002).
34. Sedlik C, Dridi A, Deriaud E et al.: Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J. Virol. 73, 2739-2744 (1999).
35. Ghosh MK, Li CL, Fayolie C et al.: Induction of HLA-A2-restricted CTL responses by a tubular structure carrying human melanoma epitopes. Vaccine. 20, 2463-2473 (2002).
36. Zamorano P, Wigdorovitz A, Chaher MT et al.: Recognition of B and T cell epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV O1 Campos. Virology 201, 383-387 (1994).
37. Hanke T, McMichael AJ: Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6, 951-955 (2000).
38. Burton DR, Desrosiers RC, Doms RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
39. Larke N, Murphy A, Wirblich C et al.: Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J. Virol. 79, 14822-14833 (2005).
40. Smith ML, Corbo T, Bernales J et al.: Assembly of trans-encapsidated recombinant viral vectors engineered from tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens. Virology 358, 321-333 (2007).
41. Mao C, Solis DJ, Reiss BD et al.: Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science 303, 213-217 (2004).
42. Flynn CE, Lee S-W, Peelle BR, Belcher AM: Viruses as vehicles for growth, organization and assembly of materials. Acta Mater. 51, 5867-5880 (2003).
43. Shenton W, TDMYGSSM: Inorganic-organic nanotube composites from template mineralization of tobacco mosaic virus. Adv. Mater. 11, 253-256 (1999).
44. Kraiselburd EN, Salaman A, Beltran M et al.: Vaccine evaluation studies of replication-defective SIVsmB7. Cell. Mol. Biol. (Noisy-le-grand) 43, 915-924 (1997).
45. Tseng RJ, Tsai C, Ma L et al.: Digital memory device based on tobacco mosaic virus conjugated with nanoparticles. Nat. Nano. 1, 72-77 (2006).
46. Hewat EA, Booth TF, Roy P: Structure of bluetongue virus particles by cryoelectron microscopy. J. Struct. Biol. 109, 61-69 (1992).